MYD88 Expression and L265P Mutation in Mature B-Cell Non-Hodgkin Lymphomas-Reference-Cited by-同舟云学术

MYD88 Expression and L265P Mutation in Mature B-Cell Non-Hodgkin Lymphomas

Published:2015-07 Issue:7 Volume:19 Page:372-378
ISSN:1945-0265
Container-title:Genetic Testing and Molecular Biomarkers
language:en
Short-container-title:Genetic Testing and Molecular Biomarkers

Author:

Caner Vildan¹,Sen Turk Nilay²,Baris Ikbal Cansu³,Cetin Gokhan Ozan¹,Tepeli Emre¹,Hacioglu Sibel⁴,Sari Ismail⁴,Zencir Sevil³,Dogu Mehmet Hilmi⁴,Bagci Gulseren¹,Keskin Ali⁴

Affiliation:

1. Tibbi Genetik AD, Pamukkale Universitesi Hastanesi, Denizli, Turkey.

2. Tibbi Patoloji AD, Pamukkale Universitesi Hastanesi, Denizli, Turkey.

3. Tibbi Biyoloji AD, Pamukkale Universitesi, Denizli, Turkey.

4. Hematoloji BD, Pamukkale Universitesi Hastanesi, Denizli, Turkey.

Publisher

Mary Ann Liebert Inc

Link

http://www.liebertpub.com/doi/pdf/10.1089/gtmb.2015.0041

Reference27 articles.

1. Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

2. Toll-like receptor signalling

3. Targetable activating mutations are very frequent in GCB and ABC diffuse large B‐cell lymphoma

4. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma

5. Acquisition of MYD88 L265P mutation during treatment of diffuse large B cell lymphoma of the parotid gland

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients;Journal of the Egyptian National Cancer Institute;2024-10-14

2. Evaluation of NFKB1 and MyD88 expression levels in a sample of non-Hodgkin lymphoma patients before and during chemotherapy;Egyptian Journal of Basic and Applied Sciences;2024-05-11

3. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis;Medicine;2024-02-09

4. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era;Leukemia Research;2020-10

5. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma;Applied Immunohistochemistry & Molecular Morphology;2019-04